重新引入芬拉胺作为治疗发作的方法:当前知识,建议和理解差距
Gianluca Dini1, Giuseppe Di Cara1, Pietro Ferrara2
1Department of Pediatrics, University of Perugia, Perugia, Italy.
芬拉胺 (FFA) 是一种抗肥胖药物,作为一种抗发作药物显示出前景. 它的潜力几十年前就被观察到,现在已经导致针对特定综合征的成功治疗.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 的研究研究.
背景情况:
- 影响着数以百万计的人,许多患者对当前的治疗没有反应.
- 芬拉胺 (FFA),最初是一种抗肥胖药物,已经成为一种潜在的抗治疗方法.
- 尽管在20世纪80年代早些时候进行了观察,但FFA的抗性质直到晚些时候才得到充分研究.
研究的目的:
- 为了回顾黄胺 (FFA) 作为抗发作治疗的历史发展.
- 追踪FFA从最初的临床观察到成功的临床试验的旅程.
- 提供FFA在管理中的重用概述.
主要方法:
- 历史数据的叙述性审查.
- 早期临床观察的分析.
- 检查临床前研究和临床试验结果.
主要成果:
- 芬拉胺 (FFA) 已成功重新用于治疗.
- 监管机构已批准FFA用于德拉维特综合征和伦诺克斯-加斯托综合征.
- 现在已经证实了FFA的抗发作作用,最初在光敏感性中发现了这种作用.
结论:
- 芬胺 (FFA) 代表了药物治疗的重大进展.
- FFA的重新定位突显了现有药物在新的治疗应用中的潜力.
- 对FFA在的机制和应用进行进一步的研究是有必要的.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
